about
Antifungal susceptibility testing: current role from the clinical laboratory perspectiveTipping the balance both ways: drug resistance and virulence in Candida glabrataAntifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileA Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection.Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Analysis of strain relatedness using high resolution melting in a case of recurrent candiduriaFrequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelCurrent perspectives on echinocandin class drugs.Detection and investigation of invasive mould disease.Antifungal resistance and new strategies to control fungal infections.Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey.Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B.EUCAST and CLSI: How to Assess in Vitro Susceptibility and Clinical ResistanceThe State-of-the-Art Mycology Laboratory: Visions of the Future
P2860
Q26862478-E9CF099A-6D2E-400B-8C6A-7D93DA63E180Q26996199-1F208346-A003-47D7-AC4D-0764768FDB35Q28489096-E7BF5B0A-E1FA-4203-85BC-190268E92ACBQ30844823-D2ABAA1E-6F3F-4709-84D3-08A75D66F7CEQ34187936-0AC15CBB-1A2A-4DFD-B69B-36C67B7B2375Q34532546-1B49F433-1904-4C98-B78B-85AF323293C5Q34559832-EF6A4A70-B979-4717-BD62-ED797CAF2968Q34737476-D4266E1B-D100-4985-B84A-F59D336A5B17Q35666627-3A62D831-FE50-4E7B-B6F6-CBA1F38C755EQ37554055-9E21FD24-3355-4E62-AB6B-F7C649CED98BQ37823011-077048B2-7D9D-4ACF-ABED-0005E8DD8A85Q39751373-520A776F-1FA0-460E-8575-1EA5B11310CCQ46862646-E6A33B28-977E-454D-B790-7A1BB86A3B65Q55437790-E4AEBE0B-BA7A-4B77-82CD-26AE87595689Q57651693-5E2FB344-F3C7-44B2-A4D5-F8189A480D1CQ59294372-5D2C5DDB-1D67-4776-AB5E-ACE776A6CEE7
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
EUCAST breakpoints for antifungals.
@en
EUCAST breakpoints for antifungals.
@nl
type
label
EUCAST breakpoints for antifungals.
@en
EUCAST breakpoints for antifungals.
@nl
prefLabel
EUCAST breakpoints for antifungals.
@en
EUCAST breakpoints for antifungals.
@nl
P2093
P1476
EUCAST breakpoints for antifungals.
@en
P2093
J Peter Donnelly
Juan L Rodríguez-Tudela
Maiken C Arendrup
Manuel Cuenca-Estrella
P356
10.1358/DNP.2010.23.2.1400855
P577
2010-03-01T00:00:00Z